Whitehawk Therapeutics, Inc.
WHWK evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for WHWK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · WHWK
Whitehawk Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody-drug conjugate (ADC) therapies, having divested its only commercial product FYARRO and now advancing a pipeline of ADC candidates through early-stage clinical trials.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$263.4M
Cash Runway
38.3 moLead Asset
fyarro (Phase 2)
Next Catalyst
Patent_Expiry · Oct 28, 2040Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 2 clinical trials · 1 catalyst for Whitehawk Therapeutics, Inc..
Whitehawk Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody-drug conjugate (ADC) therapies, having divested its only commercial product FYARRO and now advancing a pipeline of ADC candidates through early-stage clinical trials.
- As of June 30, 2026, Whitehawk had $190.0 million in cash, cash equivalents and short-term investments, with an accumulated deficit of $392.1 million [sec_mda · as of 2026-08-06].
- The company reported a net loss of $38.8 million for the six months ended June 30, 2026, compared to net income of $90.4 million in the same period of 2025, which included a gain from the FYARRO divestiture [sec_mda · as of 2026-08-06].
- Whitehawk has in-licensed ADC therapies from WuXi Biologics, paying $6.0 million in Q4 2024 and $38.0 million in Q2 2025, plus a 6% VAT fee [sec_mda · as of 2026-08-06].
- The company expects to submit an IND for HWK-206 by mid-2026 and anticipates data readouts from HWK-007 and HWK-016 Phase 1 trials in the first half of 2027 [sec · filed 2026-05-29].
- Whitehawk believes its existing cash will fund planned operations into the second half of 2028 [sec_mda · as of 2026-08-06].
What works
- Whitehawk has a cash runway into the second half of 2028, providing a multi-year development horizon without near-term financing pressure [sec_mda · as of 2026-08-06].
- The company has secured a pipeline of ADC therapies through a license agreement with WuXi Biologics, a major contract development and manufacturing organization [sec_mda · as of 2026-08-06].
- Whitehawk is advancing multiple clinical-stage programs, with Phase 1 data readouts for HWK-007 and HWK-016 expected in the first half of 2027 [sec · filed 2026-05-29].
What to weigh
- Whitehawk has no approved products or revenue sources following the FYARRO divestiture, and does not expect to generate further revenue for the foreseeable future [sec_mda · as of 2025-11-06].
- The company has an accumulated deficit of $392.1 million as of June 30, 2026, reflecting years of operating losses [sec_mda · as of 2026-08-06].
- Whitehawk's pipeline is entirely preclinical or early-stage clinical, with no guarantee of successful development or regulatory approval for any ADC candidate [sec · filed 2026-05-29].
- The company is dependent on third parties for manufacturing and clinical trial execution, introducing operational and supply-chain risks [sec · filed 2026-05-29].
From the filings
Quoted directly from source documents.
Cash position and runway
“As of June 30, 2026 we had $190.0 million of cash, cash equivalents and short-term investments. Based on our current plans, we believe our existing cash, cash equivalents and short-term investments will enable us to conduct our planned operations into the second half of 2028.”
SEC MD&A · August 6, 2026
Accumulated deficit
“As of June 30, 2026, we had an accumulated deficit of $392.1 million.”
SEC MD&A · August 6, 2026
Net loss for six months ended June 30, 2026
“Our net loss was $38.8 million and net income of”
SEC MD&A · August 6, 2026
License payments to WuXi Biologics
“Under the License Agreement, we paid non-refundable license fees of $6.0 million and $38.0 million to WuXi Biologics in the fourth quarter of 2024 and the second quarter of 2025, respectively, plus a 6% VAT fee.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2040-10-28 · Patent_Expiry · FYARRO — Patent/Exclusivity Expiry: FYARRO — Patent/exclusivity expiry for FYARRO, though the asset has been divested.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Whitehawk has no marketed products after the FYARRO divestiture and expects no revenue for the foreseeable future [sec_mda · as of 2025-11-06].
- Early-stage pipeline uncertainty — All ADC candidates are preclinical or Phase 1; clinical failure or regulatory delays could halt development [sec · filed 2026-05-29].
- Dependence on third parties — The company relies on third parties for manufacturing and clinical trials, introducing operational and supply-chain risks [sec · filed 2026-05-29].
- Significant accumulated deficit — Accumulated deficit of $392.1 million as of June 30, 2026, with ongoing net losses [sec_mda · as of 2026-08-06].
What to watch
- IND submission for HWK-206 expected by mid-2026 [sec · filed 2026-05-29].
- Phase 1 data readouts for HWK-007 and HWK-016 anticipated in the first half of 2027 [sec · filed 2026-05-29].
- Cash burn rate and any need for additional financing as the company advances its ADC pipeline [sec_mda · as of 2026-08-06].
- Progress of the WuXi Biologics license agreement and any development milestones that could trigger additional payments [sec_mda · as of 2026-08-06].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 20, 2026 · How we verify sources →
Run Whitehawk Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Whitehawk Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
38.3 months
D/E 0.06 · 0% dilution
Lead: Phase 2
4 candidates
1 upcoming, next in ~5173d
0 buys · 11 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
58
Total value held
$87.9M
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 4,166,000 | $14.4M |
| suvretta capital management, llc | 3,700,000 | $12.8M |
| acuta capital partners, llc | 3,410,402 | $11.8M |
| vanguard capital management llc | 2,631,540 | $9.1M |
| kvp capital advisors, lp | 2,165,997 | $7.5M |
| stempoint capital lp | 1,878,738 | $6.5M |
| acorn capital advisors, llc | 1,139,363 | $3.9M |
| ally bridge group (ny) llc | 817,939 | $2.8M |
| woodline partners lp | 562,994 | $1.9M |
| balyasny asset management l.p. | 550,441 | $1.9M |
Showing top 10 of 58 institutional holders of Whitehawk Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 2.2%
- Days to cover
- 4.0
- Shares short
- 780,056
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
WHWK short interestGovernance
Frequently asked questions
What is the AI investment thesis for Whitehawk Therapeutics, Inc.?
Whitehawk Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody-drug conjugate (ADC) therapies, having divested its only commercial product FYARRO and now advancing a pipeline of ADC candidates through early-stage clinical trials.
What is Whitehawk Therapeutics, Inc.'s lead drug candidate?
Whitehawk Therapeutics, Inc.'s most advanced tracked candidate is fyarro (Phase 2) for Neuroendocrine tumors (NETs) of the GI tract, lung, or pancreas.
What is Whitehawk Therapeutics, Inc.'s next catalyst?
Whitehawk Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: FYARRO" — expected October 28, 2040.
Who is the CEO of Whitehawk Therapeutics, Inc.?
Dr. David J. Lennon Ph.D. is the chief executive officer of Whitehawk Therapeutics, Inc. (WHWK).
Where is Whitehawk Therapeutics, Inc. headquartered?
Whitehawk Therapeutics, Inc. (WHWK) is headquartered in Morristown, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.